73963-72-1 | 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$7.00	$5.00
250mg	98%	in stock	$9.00	$6.00
1g	98%	in stock	$18.00	$13.00
5g	98%	in stock	$29.00	$20.00
25g	98%	in stock	$96.00	$68.00
100g	98%	in stock	$299.00	$209.00
250g	≥ 99% (Assay)	in stock	$526.00	$368.00
1kg	≥ 99% (Assay)	in stock	$1,812.00	$1,268.00

Description

• Catalog Number: AB72043
• Chemical Name: 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
• CAS Number: 73963-72-1
• Molecular Formula: C20H27N5O2
• Molecular Weight: 369.4607
• MDL Number: MFCD00866780
• SMILES: O=C1CCc2c(N1)ccc(c2)OCCCCc1nnnn1C1CCCCC1
• NSC Number: 758936

Computed Properties

• Complexity: 485
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 3.1

Literature

• A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm.

  Toxicology and applied pharmacology 20170215

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid.

  Annals of clinical and translational neurology 20140801

• Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: targeting for cilostazol.

  Journal of neuroscience research 20140201

• Pancreatic β-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes.

  Diabetes, obesity & metabolism 20121101

• Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.

  Diabetes care 20121101

• Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats.

  Biopharmaceutics & drug disposition 20121101

• Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats.

  The Journal of pharmacy and pharmacology 20121101

• Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.

  Acta cirurgica brasileira 20121101

• Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20121001

• The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.

  Clinical cardiology 20121001

• Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.

  Thrombosis research 20121001

• Angiographic restenosis and its clinical impact after infrapopliteal angioplasty.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20121001

• Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.

  Life sciences 20120917

• Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity.

  European journal of pharmacology 20120915

• Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

  Journal of the neurological sciences 20120915

• Quantitative assessment of changes in carotid plaques during cilostazol administration using three-dimensional ultrasonography and non-gated magnetic resonance plaque imaging.

  Neuroradiology 20120901

• Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke.

  Clinical neurology and neurosurgery 20120901

• The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimus-eluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry.

  Cardiovascular intervention and therapeutics 20120901

• Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study.

  Arzneimittel-Forschung 20120901

• Indomethacin-induced small intestinal injury is ameliorated by cilostazol, a specific PDE-3 inhibitor.

  Scandinavian journal of gastroenterology 20120901

• A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol.

  Journal of geriatric cardiology : JGC 20120901

• K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.

  European journal of pharmacology 20120815

• Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.

  The Cochrane database of systematic reviews 20120815

• Cilostazol prevents progression of asymptomatic carotid artery stenosis in patients with contralateral carotid artery stenting.

  AJNR. American journal of neuroradiology 20120801

• A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.

  Clinical science (London, England : 1979) 20120801

• Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms syndrome induced by cilostazol and carbamazepine.

  The Journal of dermatology 20120801

• Protection by cilostazol against amyloid-β(1-40)-induced suppression of viability and neurite elongation through activation of CK2α in HT22 mouse hippocampal cells.

  Journal of neuroscience research 20120801

• Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb.

  Journal of vascular surgery 20120801

• Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.

  Journal of thrombosis and haemostasis : JTH 20120801

• Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?

  Minerva cardioangiologica 20120801

• Cilostazol and primary-PCI: mirage or good alternative?

  Current vascular pharmacology 20120701

• Two-wavelength near-infrared fluorescence for the quantitation of drug antiplatelet effects in large animal model systems.

  Journal of vascular surgery 20120701

• Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study.

  Stroke 20120701

• Cilostazol in NICE guideline.

  Heart (British Cardiac Society) 20120701

• Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.

  The international journal of cardiovascular imaging 20120601

• Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol.

  Stroke 20120601

• L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.

  Vascular medicine (London, England) 20120601

• Use of cilostazol in percutaneous coronary interventions.

  The Annals of pharmacotherapy 20120601

• Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.

  The Korean journal of internal medicine 20120601

• Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome.

  Korean circulation journal 20120601

• Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation.

  Experimental & molecular medicine 20120531

• Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention.

  The American journal of cardiology 20120515

• Peripheral arterial disease of the lower extremities.

  Archives of medical science : AMS 20120509

• [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention].

  No shinkei geka. Neurological surgery 20120501

• [Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)].

  Deutsche medizinische Wochenschrift (1946) 20120501

• Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects.

  International journal of clinical pharmacology and therapeutics 20120501

• Regarding the 'Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study'.

  American heart journal 20120501

• Successful percutaneous coronary intervention in a centenarian patient with acute myocardial infarction.

  Korean circulation journal 20120501

• Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.

  Journal of applied biomechanics 20120501

• Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20120401

• Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

  British journal of clinical pharmacology 20120401

• Control of cilostazol release kinetics and direction from a stent using a reservoir-based design.

  Journal of biomedical materials research. Part B, Applied biomaterials 20120401

• Cilostazol induces cellular senescence and confers resistance to etoposide-induced apoptosis in articular chondrocytes.

  International journal of molecular medicine 20120401

• Cilostazol Decreases Ethanol-Mediated TNFalpha Expression in RAW264.7 Murine Macrophage and in Liver from Binge Drinking Mice.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20120401

• Clinical outcomes of infrapopliteal angioplasty in patients with critical limb ischemia.

  Korean circulation journal 20120401

• Effects of weight change on clinical outcomes in overweight and obese patients with acute myocardial infarction who underwent successful percutaneous coronary intervention.

  Chonnam medical journal 20120401

• Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120301

• Improved antiplatelet therapy? There's a generic thought.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120301

• Use of cilostazol for secondary stroke prevention: an old dog with new tricks?

  The Annals of pharmacotherapy 20120301

• Regarding 'Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia'.

  Journal of vascular surgery 20120301

• The relevance of the primary prevention criteria for implantable cardioverter defibrillator implantation in korean symptomatic severe heart failure patients.

  Korean circulation journal 20120301

• Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study.

  Journal of the neurological sciences 20120215

• Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility.

  Journal of pharmaceutical sciences 20120201

• Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.

  Stroke 20120201

• Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical limb ischemia presenting with isolated below-the-knee lesions.

  Journal of vascular surgery 20120201

• Novel antiplatelet therapies.

  Current atherosclerosis reports 20120201

• A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.

  Journal of vascular surgery 20120201

• P2Y12 platelet inhibition in clinical practice.

  Journal of thrombosis and thrombolysis 20120201

• Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells.

  Journal of vascular surgery 20120201

• Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway.

  Clinics (Sao Paulo, Brazil) 20120201

• Recurrent very late stent thrombosis in a systemic lupus erythematous patient.

  Korean circulation journal 20120201

• Curcumin increases vasodilatory effect of cilostazol in diabetic rat aorta.

  Indian journal of experimental biology 20120201

• Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.

  Revista espanola de cardiologia (English ed.) 20120101

• Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20120101

• Antiplatelet, Antithrombotic, and Fibrinolytic Activities of Campomanesia xanthocarpa.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials.

  Atherosclerosis 20120101

• New and old mechanisms associated with hypertension in the elderly.

  International journal of hypertension 20120101

• Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.

  Experimental neurology 20120101

• Recent advances in epidural analgesia.

  Anesthesiology research and practice 20120101

• Options to overcome clopidogrel response variability.

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• [Chronic peripheral arterial disease induced by cocaine].

  Medicina 20120101

• Identification of unique expression signatures and therapeutic targets in esophageal squamous cell carcinoma.

  BMC research notes 20120101

• Perspectives of Targeting mTORC1-S6K1 in Cardiovascular Aging.

  Frontiers in physiology 20120101

• The role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice.

  PloS one 20120101

• An ulceronecrotic foot lesion in a patient with essential thrombocythemia: successful treatment with hydroxyurea.

  Case reports in dermatology 20120101

• Small vessel cerebrovascular disease: the past, present, and future.

  Stroke research and treatment 20120101

• Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.

  PloS one 20120101

• Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.

  Frontiers in pharmacology 20120101

• Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

  Cardiology research and practice 20120101

• Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study.

  Surgical neurology international 20120101

• A new antiplatelet agent cilostazol--what is the evidence for its use and tolerability?

  JPMA. The Journal of the Pakistan Medical Association 20120101

• A case of late stent thrombosis following platelet transfusion in a patient with aplastic anemia.

  Korean circulation journal 20120101

• Non-occlusive mesenteric ischemia and the role of cilostazol in its management.

  Journal of pharmacology & pharmacotherapeutics 20120101

• Evolving role of platelet function testing in coronary artery interventions.

  Vascular health and risk management 20120101

• Forskolin and derivatives as tools for studying the role of cAMP.

  Die Pharmazie 20120101

• Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention.

  International heart journal 20120101

• Recovery of normal hemodynamic activities after long-term medication in a patient with left internal carotid arterial occlusion.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20120101

• Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

  Vascular health and risk management 20120101

• A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.

  Internal medicine (Tokyo, Japan) 20120101

• Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.

  Nutrition & metabolism 20120101

• The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.

  Trials 20120101

• The putative tumor suppressor VILIP-1 counteracts epidermal growth factor-induced epidermal-mesenchymal transition in squamous carcinoma cells.

  PloS one 20120101

• [Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation].

  Zhonghua xin xue guan bing za zhi 20120101

• Rapid formation of cerebral microbleeds after carotid artery stenting.

  Cerebrovascular diseases extra 20120101

• [Augmentation therapy with cilostazol for the intractable geriatric major depressive disorder patients with deep white matter hyperintensities on T2-weighted brain MRI].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101

• Stent thrombosis: incidence, predictors and new technologies.

  Thrombosis 20120101

• 2-decenoic acid ethyl ester, a compound that elicits neurotrophin-like intracellular signals, facilitating functional recovery from cerebral infarction in mice.

  International journal of molecular sciences 20120101

• Preparation and characterization of micronized artemisinin via a Rapid Expansion of Supercritical Solutions (RESS) Method.

  International journal of molecular sciences 20120101

• Characteristics and clinical managements of chronic skin ulcers based on traditional chinese medicine.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Surface modification of biomaterials: a quest for blood compatibility.

  International journal of biomaterials 20120101

• Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits.

  PloS one 20120101

• Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.

  Journal of pharmacological sciences 20120101

• Retraction of: Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention.

  International heart journal 20120101

• A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.

  Cardiology 20120101

• Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.

  Cardiology 20120101

• Cilostazol and diltiazem attenuate cyclosporine-induced nephrotoxicity in rats.

  Transplantation proceedings 20120101

• Vinpocetine inhibits oligodendroglial precursor cell differentiation.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

• Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.

  International journal of medical sciences 20120101

• Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.

  Journal of translational medicine 20120101

• Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance.

  Vascular health and risk management 20120101

• Targeting phosphodiesterases in anti-platelet therapy.

  Handbook of experimental pharmacology 20120101

• Antiplatelet therapy in cerebrovascular disorders.

  Handbook of experimental pharmacology 20120101

• Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation.

  PloS one 20120101

• Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol.

  Pharmacology 20120101

• K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.

  PloS one 20120101

• Clinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients.

  PloS one 20120101

• Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.

  Clinical and experimental nephrology 20111201

• Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia.

  Journal of vascular surgery 20111201

• Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.

  Cardiovascular therapeutics 20111201

• Loading solution prevents activation damage of human platelets before lyophilization.

  Cryobiology 20111201

• A selective phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control.

  American journal of physiology. Heart and circulatory physiology 20111201

• Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.

  Clinical therapeutics 20111201

• Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study.

  American heart journal 20111201

• A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.

  Health technology assessment (Winchester, England) 20111201

• Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20111201

• Peripheral arterial disease and abdominal aortic aneurysm in elderly people.

  Minerva medica 20111201

• Very Late Stent Thrombosis due to Neointimal Rupture After Paclitaxel-Eluting Stent Implantation.

  Korean circulation journal 20111201

• Successful hybrid operation of an acute mobile thrombus in the abdominal aorta induced by chemotherapy.

  Journal of the Korean Surgical Society 20111201

• cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

  Current neuropharmacology 20111201

• Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells.

  European journal of pharmacology 20111130

• Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials.

  International journal of cardiology 20111117

• Cilostazol in diabetic neuropathy: premature farewell or new beginning?

  Angiology 20111101

• Genetic determinants of platelet response to clopidogrel.

  Journal of thrombosis and thrombolysis 20111101

• Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND).

  Angiology 20111101

• Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.

  Annals of medicine 20111101

• Cilostazol determination by the enhancement of the green emission of Tb3+ optical sensor.

  Journal of fluorescence 20111101

• [Preparation of two poor water soluble drugs - nanoporous ZnO solid dispersions and the mechanism of drug dissolution improvement].

  Yao xue xue bao = Acta pharmaceutica Sinica 20111101

• Effect of dibutyryl cyclic adenosine monophosphate on the gene expression of plasminogen activator inhibitor-1 and tissue factor in adipocytes.

  Thrombosis research 20111001

• Cilostazol minimizes venous ischemic injury in diabetic and normal rats.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20111001

• Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.

  Clinical research in cardiology : official journal of the German Cardiac Society 20111001

• Anti-platelet therapy: phosphodiesterase inhibitors.

  British journal of clinical pharmacology 20111001

• Effect of type II endoleaks and antiplatelet therapy on abdominal aortic aneurysm shrinkage after endovascular repair.

  Journal of vascular surgery 20111001

• Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.

  Clinical and experimental pharmacology & physiology 20111001

• Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?

  Clinical and experimental pharmacology & physiology 20111001

• Sex differences in pharmacokinetics of cilostazol in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20111001

• Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.

  Stroke 20111001

• Cilostazol suppresses angiotensin II-induced vasoconstriction via protein kinase A-mediated phosphorylation of the transient receptor potential canonical 6 channel.

  Arteriosclerosis, thrombosis, and vascular biology 20111001

• Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20111001

• Advances in tenascin-C biology.

  Cellular and molecular life sciences : CMLS 20111001

• Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial.

  Journal of clinical psychopharmacology 20111001

• Use of prasugrel in a patient with clopidogrel hypersensitivity.

  The Annals of pharmacotherapy 20111001

• Retraction of: Cilostazol inhibits cytokine-induced nuclear factor-κB activation via AMP-activated protein kinase activation in vascular endothelial cells.

  Cardiovascular research 20111001

• Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/magnetic resonance angiography.

  Advances in therapy 20111001

• [Vagal stimulation - a new possibility for conservative treatment of peripheral arterial occlusion disease].

  Zentralblatt fur Chirurgie 20111001

• [Interims analysis of a prospective observational study on the use of cilostazol (Pletal®) in daily clinical vascularsurgical practice].

  Zentralblatt fur Chirurgie 20111001

• The Association between Carotid Atherosclerosis and Glucose.

  Diabetes & metabolism journal 20111001

• Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation.

  Korean circulation journal 20111001

• Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.

  Heart and vessels 20110901

• Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway.

  Arteriosclerosis, thrombosis, and vascular biology 20110901

• A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention.

  Yonsei medical journal 20110901

• Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.

  Stroke 20110901

• Beyond phosphorylation: nuclear export in vascular remodeling.

  Arteriosclerosis, thrombosis, and vascular biology 20110901

• [Cilostazol].

  Nihon rinsho. Japanese journal of clinical medicine 20110901

• Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia.

  The Journal of pharmacology and experimental therapeutics 20110801

• Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).

  Current atherosclerosis reports 20110801

• Current management of symptomatic intracranial stenosis.

  Current atherosclerosis reports 20110801

• Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?

  Current cardiology reports 20110801

• Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.

  Thrombosis and haemostasis 20110801

• Medical management of the patient with intermittent claudication.

  Cardiology clinics 20110801

• Cilostazol Inhibits Vascular Smooth Muscle Cell Proliferation and Reactive Oxygen Species Production through Activation of AMP-activated Protein Kinase Induced by Heme Oxygenase-1.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20110801

• A case of stent thrombosis occurred at 5 years after sirolimus-eluting stent implantation.

  Chonnam medical journal 20110801

• Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression.

  Biochemical and biophysical research communications 20110729

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• We need further studies for the development of 'optimized antiplatelet therapy' based on ethnicity.

  Journal of the American College of Cardiology 20110705

• Erythrocytes as controllers of perfusion distribution in the microvasculature of skeletal muscle.

  Acta physiologica (Oxford, England) 20110701

• Very Late Stent Thrombosis in a Drug-Eluting Stent due to Interruption of Anti-Platelet Agents in Patients With Acute Myocardial Infarction and Thrombocytosis.

  Korean circulation journal 20110701

• Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.

  Thrombosis research 20110601

• Interventional cardiology. Potential benefit of adding cilostazol to antiplatelet therapy after DES implantation.

  Nature reviews. Cardiology 20110601

• Cilostazol in patients with ischemic stroke.

  Expert opinion on pharmacotherapy 20110601

• Cilostazol: a drug particularly effective for Asians?

  International journal of stroke : official journal of the International Stroke Society 20110601

• Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.

  Cardiovascular drugs and therapy 20110601

• Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury.

  The heart surgery forum 20110601

• [Management of NSAIDs and low-dose-aspirin-induced ulcer in patients with cerebral infarction].

  Nihon rinsho. Japanese journal of clinical medicine 20110601

• Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.

  The Korean journal of internal medicine 20110601

• Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation.

  Biochemical and biophysical research communications 20110520

• Cilostazol: a potential therapeutic option to prevent in-stent restenosis.

  Journal of the American College of Cardiology 20110517

• Suppression of experimental abdominal aortic aneurysm in a rat model by the phosphodiesterase 3 inhibitor cilostazol.

  The Journal of surgical research 20110515

• Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation.

  Angiology 20110501

• New perspectives for the treatment of pulmonary hypertension.

  British journal of pharmacology 20110501

• Induction of heme oxygenase-1 expression by cilostazol contributes to its anti-inflammatory effects in J774 murine macrophages.

  Immunology letters 20110501

• Cilostazol enhances integrin-dependent homing of progenitor cells by activation of cAMP-dependent protein kinase in synergy with Epac1.

  Journal of neuroscience research 20110501

• Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients.

  The International journal of neuroscience 20110501

• cAMP regulates ADP-induced HSP27 phosphorylation in human platelets.

  International journal of molecular medicine 20110501

• Blockade of phosphodiesterase-III protects against oxygen-glucose deprivation in endothelial cells by upregulation of VE-cadherin.

  Current neurovascular research 20110501

• A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

  European heart journal 20110401

• Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.

  The American journal of cardiology 20110401

• Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.

  Heart (British Cardiac Society) 20110401

• Protective effect of pretreatment with cilostazol on cytotoxicity of cadmium and arsenite in cultured vascular endothelial cells.

  The Journal of toxicological sciences 20110401

• [Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110401

• Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction.

  Journal of Korean medical science 20110401

• Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.

  The Korean journal of laboratory medicine 20110401

• Impact of cilostazol on left ventricular geometry and function: assessment by tissue Doppler imaging and two-dimensional speckle-tracking echocardiography.

  Echocardiography (Mount Kisco, N.Y.) 20110401

• Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

  JACC. Cardiovascular interventions 20110401

• HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20110401

• A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.

  Journal of the American College of Cardiology 20110315

• Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension.

  Angiogenesis 20110301

• Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

  Expert opinion on pharmacotherapy 20110301

• [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20110301

• Endothelial dysfunction in the smokers can be improved with oral cilostazol treatment.

  Journal of cardiovascular ultrasound 20110301

• Pharmacologic modulation of experimentally induced allergic asthma.

  Interdisciplinary toxicology 20110301

• Filariasis in Japan some 25 years after its eradication.

  Tropical medicine and health 20110301

• Inhibition of ATP release from erythrocytes: a role for EPACs and PKC.

  Microcirculation (New York, N.Y. : 1994) 20110201

• Effects of cilostazol in the heart.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20110201

• Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.

  Anesthesia and analgesia 20110201

• Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?

  Biomarkers in medicine 20110201

• What are the therapeutic options for strokes secondary to intracranial large artery stenosis?

  JPMA. The Journal of the Pakistan Medical Association 20110201

• [Lower limb arterial disease--nothing new since the SBU report].

  Lakartidningen 20110201

• Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.

  The Cochrane database of systematic reviews 20110119

• Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.

  Journal of the American College of Cardiology 20110118

• Connective tissue reflex massage for type 2 diabetic patients with peripheral arterial disease: randomized controlled trial.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Cilostazol increases skin perfusion pressure in severely ischemic limbs.

  Angiology 20110101

• A combined treatment for acute larger lacunar-type infarction.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20110101

• Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20110101

• Spectroscopic studies on the interaction of cilostazole with iodine and 2,3-dichloro-5,6-dicyanobenzoquinone.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110101

• Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits.

  Acta neurochirurgica. Supplement 20110101

• What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?

  Journal of cardiology 20110101

• Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol.

  Platelets 20110101

• Cilostazol inhibits cytokine-induced tetrahydrobiopterin biosynthesis in human umbilical vein endothelial cells.

  Journal of atherosclerosis and thrombosis 20110101

• Extrapleural hematoma as a complication following thoracotomy for pulmonary lobectomy.

  General thoracic and cardiovascular surgery 20110101

• Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.

  Trials 20110101

• Cilostazol improves symptomatic intracranial artery stenosis - Evaluation of cerebral blood flow with single photon emission computed tomography.

  Surgical neurology international 20110101

• Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Stenting of the Left Main Coronary Artery in a Patient With Takayasu's Arteritis.

  Korean circulation journal 20110101

• In vitro dissolution/permeation system to predict the oral absorption of poorly water-soluble drugs: effect of food and dose strength on it.

  Biological & pharmaceutical bulletin 20110101

• The door is open and the next step is forthcoming--lesson from J-SMART registry.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol.

  PloS one 20110101

• DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities.

  Journal of biomedicine & biotechnology 20110101

• The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel.

  Thrombosis journal 20110101

• Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay.

  Internal medicine (Tokyo, Japan) 20110101

• Peripheral arterial disease.

  BMJ clinical evidence 20110101

• Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells.

  PloS one 20110101

• Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke.

  Journal of pharmacological sciences 20110101

• Pneumatosis intestinalis leading to perioperative hypovolemic shock: Case report.

  World journal of emergency surgery : WJES 20110101

• β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D.

  PloS one 20110101

• Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.

  Trials 20110101

• Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.

  Cerebrovascular diseases (Basel, Switzerland) 20110101

• [Toxic epidermal necrolysis with fatal ending due to the concurrent use of carbamazepine, cilostazol and omeprazol: a case report].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report.

  Cerebrovascular diseases (Basel, Switzerland) 20110101

• Phosphodiesterases as targets for intermittent claudication.

  Handbook of experimental pharmacology 20110101

• Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial.

  Journal of atherosclerosis and thrombosis 20110101

• Pharmacodynamic interaction study of Allium sativum (garlic) with cilostazol in patients with type II diabetes mellitus.

  Indian journal of pharmacology 20110101

• Severe isolated thrombocytopenia after clopidogrel and pentoxifylline therapy: a case report.

  Journal of medical case reports 20110101

• Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20110101

• Dysthymia and apathy: diagnosis and treatment.

  Depression research and treatment 20110101

• Secondary Pharmacotherapeutic Prevention among German Primary Care Patients with Peripheral Arterial Disease.

  International journal of vascular medicine 20110101

• Nanoscale hepatoprotective herbal decoction attenuates hepatic stellate cell activity and chloroform-induced liver damage in mice.

  International journal of nanomedicine 20110101

• Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs.

  International journal of vascular medicine 20110101

• Intracranial atherosclerotic disease.

  Stroke research and treatment 20110101

• Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model.

  Journal of translational medicine 20110101

• Application of supercritical antisolvent method in drug encapsulation: a review.

  International journal of nanomedicine 20110101

• Escalation regimen of cilostazol for acute brain infarction.

  Internal medicine (Tokyo, Japan) 20110101

• Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

  BMJ (Clinical research ed.) 20110101

• Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.

  Vascular health and risk management 20110101

• Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus.

  International journal of general medicine 20110101

• Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?

  International journal of vascular medicine 20110101

• Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective.

  International journal of endocrinology 20110101

• Recovery of advanced atrioventricular block by cilostazol.

  Internal medicine (Tokyo, Japan) 20110101

• Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model.

  PloS one 20110101

• Cilostazol to overcome high on-treatment platelet reactivity in korean patients treated with clopidogrel and calcium-channel blocker.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.

  BMC systems biology 20110101

• Long-term prognosis of symptomatic isolated middle cerebral artery disease in Korean stroke patients.

  BMC neurology 20110101

• Novel agents for anti-platelet therapy.

  Journal of hematology & oncology 20110101

• Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.

  Cardiology journal 20110101

• Isoflurane-induced spatial memory impairment in mice is prevented by the acetylcholinesterase inhibitor donepezil.

  PloS one 20110101

• Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.

  International journal of nanomedicine 20110101

• Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke.

  Neurologia medico-chirurgica 20110101

• Optimal management of peripheral arterial disease for the non-specialist.

  The Ulster medical journal 20110101

• Antiplatelet resistance and thromboembolic complications in neurointerventional procedures.

  Frontiers in neurology 20110101

• Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease.

  ARYA atherosclerosis 20110101

• A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine.

  Medical devices (Auckland, N.Z.) 20110101

• Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia.

  Neuroscience 20101229

• Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy.

  The AAPS journal 20101201

• Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice.

  British journal of pharmacology 20101201

• Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.

  Thrombosis and haemostasis 20101201

• Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.

  Clinical therapeutics 20101201

• Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders.

  Journal of thrombosis and haemostasis : JTH 20101101

• Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo.

  Atherosclerosis 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.

  Journal of Korean medical science 20101101

• Stroke: cilostazol [corrected] demonstrates noninferiority to aspirin for the prevention of recurrent stroke.

  Nature reviews. Neurology 20101101

• A case of intra- and extra-mural hematomas during recanalization for chronic total occlusion.

  Korean circulation journal 20101101

• [Report from International Stroke Conference 2010, San Antonio, USA].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20101101

• [Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].

  Rinsho shinkeigaku = Clinical neurology 20101101

• [Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients].

  Rinsho shinkeigaku = Clinical neurology 20101101

• [New clinical concept and therapeutic strategy for TIA].

  Rinsho shinkeigaku = Clinical neurology 20101101

• [Concept of branch atheromatous disease (BAD) and its clinical significance].

  Rinsho shinkeigaku = Clinical neurology 20101101

• Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway.

  Journal of atherosclerosis and thrombosis 20101027

• Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.

  Neurological research 20101001

• Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.

  Journal of cellular and molecular medicine 20101001

• Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.

  Circulation. Cardiovascular interventions 20101001

• Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.

  The Lancet. Neurology 20101001

• Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.

  The Korean journal of laboratory medicine 20101001

• Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.

  Annals of the New York Academy of Sciences 20101001

• [A case of coronary stent thrombosis occurring repeatedly in the perioperative period].

  Masui. The Japanese journal of anesthesiology 20101001

• [Combination of percutaneous balloon angioplasty and aggressive medical intervention improves symptomatic basilar artery stenosis with a tortuous access route: case report].

  No shinkei geka. Neurological surgery 20101001

• [Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction].

  Zhonghua xin xue guan bing za zhi 20101001

• What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?

  JPMA. The Journal of the Pakistan Medical Association 20101001

• Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.

  Trends in cardiovascular medicine 20101001

• Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?

  International journal of cardiology 20100924

• Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100901

• Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.

  Journal of vascular surgery 20100901

• Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-kappaB inactivation: not involved in cAMP mechanisms.

  International immunopharmacology 20100901

• Office management of peripheral arterial disease.

  The American journal of medicine 20100901

• Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).

  American heart journal 20100901

• Oral antiplatelet therapy in stroke prevention. Minireview.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20100901

• Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia.

  Journal of neuroscience research 20100801

• Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20100801

• Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.

  Journal of applied biomechanics 20100801

• Peripheral artery disease: current insight into the disease and its diagnosis and management.

  Mayo Clinic proceedings 20100701

• Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.

  JACC. Cardiovascular interventions 20100701

• Fatal renal bleeding in a patient treated with aggressive antithrombotic therapy after recurrent coronary stent thrombosis.

  Korean circulation journal 20100701

• Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells.

  Neuroreport 20100623

• The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.

  Circulation 20100615

• A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.

  Vascular medicine (London, England) 20100601

• Update on antithrombotic therapy for stroke prevention in atrial fibrillation.

  Current treatment options in cardiovascular medicine 20100601

• The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.

  The Korean journal of internal medicine 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Silence of the limbs pharmacological symptomatic treatment of intermittent claudication.

  Current vascular pharmacology 20100501

• Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats.

  Journal of thrombosis and thrombolysis 20100501

• Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo.

  Journal of atherosclerosis and thrombosis 20100501

• Cilostazol in the management of atherosclerosis.

  Current vascular pharmacology 20100501

• SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis.

  Journal of atherosclerosis and thrombosis 20100501

• American Society for Clinical Pharmacology and Therapeutics (ASCPT)-111th annual meeting. 17-20 March 2010, Atlanta, GA, USA.

  IDrugs : the investigational drugs journal 20100501

• [Diagnosis and treatment of cerebral infarction].

  Nihon rinsho. Japanese journal of clinical medicine 20100501

• Simultaneous multi-vessel subacute stent thromboses in zotarolimus-eluting stents.

  Korean circulation journal 20100501

• Peripheral arterial disease.

  BMJ clinical evidence 20100426

• Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors.

  European journal of pharmacology 20100425

• Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.

  International journal of cardiology 20100401

• Thienopyridine and cilostazol are safer for gastroduodenal mucosa than low-dose aspirin--second report of endoscopic evaluation.

  Thrombosis research 20100401

• Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.

  Journal of clinical pharmacology 20100401

• Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity.

  British journal of haematology 20100401

• Intrinsic sex-specific differences in microvascular endothelial cell phosphodiesterases.

  American journal of physiology. Heart and circulatory physiology 20100401

• Cilostazol effectively reduces the decrease of flow volume in a thrombotic anastomosis model in a rat: a novel application of ultrasonography for evaluation.

  Annals of plastic surgery 20100401

• Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).

  International angiology : a journal of the International Union of Angiology 20100401

• Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.

  Canadian journal of physiology and pharmacology 20100401

• Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.

  European journal of neurology 20100301

• Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100301

• The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.

  Anesthesia and analgesia 20100301

• Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.

  British journal of pharmacology 20100301

• Cilostazol enhances apoptosis of synovial cells from rheumatoid arthritis patients with inhibition of cytokine formation via Nrf2-linked heme oxygenase 1 induction.

  Arthritis and rheumatism 20100301

• A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management.

  Annals of medicine 20100301

• Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.

  The Lancet. Neurology 20100301

• Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.

  Journal of Korean medical science 20100301

• The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction.

  Korean circulation journal 20100301

• Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20100201

• Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20100201

• Protein kinases A and C regulate receptor-mediated increases in cAMP in rabbit erythrocytes.

  American journal of physiology. Heart and circulatory physiology 20100201

• Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.

  Circulation. Cardiovascular interventions 20100201

• Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives.

  Chemical & pharmaceutical bulletin 20100201

• Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome.

  International journal of clinical pharmacology and therapeutics 20100201

• Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).

  American heart journal 20100201

• Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be 'TAPT?'.

  Circulation. Cardiovascular interventions 20100201

• Insulin inhibits human erythrocyte cAMP accumulation and ATP release: role of phosphodiesterase 3 and phosphoinositide 3-kinase.

  Experimental biology and medicine (Maywood, N.J.) 20100201

• Ischemic postconditioning may not influence early brain injury induced by focal cerebral ischemia/reperfusion in rats.

  Korean journal of anesthesiology 20100201

• The effects of gabapentin pretreatment on brain injury induced by focal cerebral ischemia/reperfusion in the rat.

  Korean journal of anesthesiology 20100201

• Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

  The American journal of cardiology 20100115

• Cilostazol reduces restenosis after carotid artery stenting.

  Journal of vascular surgery 20100101

• Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions.

  Clinical & experimental metastasis 20100101

• Platelet thrombin receptor antagonism and atherothrombosis.

  European heart journal 20100101

• Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.

  Circulation journal : official journal of the Japanese Circulation Society 20100101

• Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus.

  Neuropharmacology 20100101

• Long-Term clinical outcomes according to initial management and thrombolysis in myocardial infarction risk score in patients with acute non-ST-segment elevation myocardial infarction.

  Yonsei medical journal 20100101

• Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

  British journal of clinical pharmacology 20100101

• The effect of cilostazol on stent thrombosis after drug-eluting stent implantation.

  Korean circulation journal 20100101

• Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.

  Clinical therapeutics 20100101

• In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report.

  Cases journal 20100101

• The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum.

  Advances in experimental medicine and biology 20100101

• Drug-carrying albumin film for blood-contacting biomaterials.

  Journal of biomaterials science. Polymer edition 20100101

• Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention.

  Annals of Indian Academy of Neurology 20100101

• The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.

  Journal of neuroengineering and rehabilitation 20100101

• An association between anti-platelet drug use and reduced cancer prevalence in diabetic patients: results from the Vermont Diabetes Information System Study.

  BMC cancer 20100101

• Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.

  BMC medicine 20100101

• Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB.

  Bioscience, biotechnology, and biochemistry 20100101

• Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea.

  Journal of oleo science 20100101

• Cilostazol may suppress restenosis and new contralateral carotid artery stenosis after carotid endarterectomy.

  Neurologia medico-chirurgica 20100101

• Treatment of specific macrovascular beds in patients with diabetes mellitus.

  Osteopathic medicine and primary care 20100101

• Clinical pharmacology and vascular risk.

  The open neurology journal 20100101

• Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.

  Trials 20100101

• From bench to bedside: report of the Sixth International Stroke Summit, Nanjing, China, July 9-11, 2010.

  Cerebrovascular diseases (Basel, Switzerland) 20100101

• Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes.

  Scientia pharmaceutica 20100101

• Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.

  Vascular health and risk management 20100101

• Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.

  International heart journal 20100101

• Risk assessment and aspirin use in Asian and Western populations.

  Vascular health and risk management 20100101

• Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease.

  Clinical Medicine Insights. Cardiology 20100101

• Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.

  PloS one 20100101

• Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement.

  PloS one 20100101

• Clinicoradiological features of recurrent ischemic stroke: healthcare for poststroke patients.

  Journal of multidisciplinary healthcare 20100101

• Platelets and cardiac arrhythmia.

  Frontiers in physiology 20100101

• Newer antithrombotic drugs.

  Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 20100101

• Juvenile Bow Hunter's Stroke without Hemodynamic Changes.

  Clinical medicine insights. Case reports 20100101

• Emerging antiplatelet agents, differential pharmacology, and clinical utility.

  Journal of blood medicine 20100101

• The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?

  Clinical pharmacology : advances and applications 20100101

• Peripheral arterial disease in women.

  Maturitas 20091220

• Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.

  Atherosclerosis 20091201

• Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes.

  American journal of physiology. Gastrointestinal and liver physiology 20091201

• The role of tenascin-C in tissue injury and tumorigenesis.

  Journal of cell communication and signaling 20091201

• Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.

  Neuroscience bulletin 20091201

• Prevalence of gastroduodenal mucosal injury in asymptomatic patients taking antiplatelet agents in Japan.

  International journal of clinical pharmacology and therapeutics 20091201

• Peripheral arterial disease: update of overview and treatment.

  Medicine and health, Rhode Island 20091201

• Protein kinase A-dependent suppression of reactive oxygen species in transient focal ischemia in adrenomedullin-deficient mice.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20091101

• [Peripheral arterial disease with lower limb claudication: Medical treatment].

  Journal des maladies vasculaires 20091101

• Long-term results of endovascular therapy with nitinol stent implantation for TASC II A/B femoro-popliteal artery lesions: 4 years' experience.

  Circulation journal : official journal of the Japanese Circulation Society 20091101

• [Cilostazol induces metallothionein expression in vascular cells].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20091101

• Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention.

  Hamostaseologie 20091101

• Prescriber compliance with black box warnings in older adult patients.

  The American journal of managed care 20091101

• Strategy for the treatment of clopidogrel low responsiveness in diabetes mellitus and stent implantation.

  Korean circulation journal 20091101

• Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation.

  Korean circulation journal 20091101

• [Mechanism underlying thrombus formation in cerebral infarction].

  Rinsho shinkeigaku = Clinical neurology 20091101

• Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review.

  Current cardiology reviews 20091101

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Medical treatment of patients with intracranial atherosclerotic disease.

  Journal of neuroimaging : official journal of the American Society of Neuroimaging 20091001

• The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model.

  Turkish neurosurgery 20091001

• Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers.

  Clinical therapeutics 20091001

• Cilostazol may improve outcome in critical limb ischemia.

  International angiology : a journal of the International Union of Angiology 20091001

• Therapeutic strategy for in-stent restenosis based on the restenosis pattern after drug-eluting stent implantation.

  Korean circulation journal 20091001

• Acute and subacute stent thrombosis in a patient with clopidogrel resistance: a case report.

  Korean circulation journal 20091001

• Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting.

  The American journal of cardiology 20090907

• Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.

  Clinical pharmacology and therapeutics 20090901

• Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats.

  The Journal of pharmacology and experimental therapeutics 20090901

• New antiplatelet agents.

  Current opinion in hematology 20090901

• [Implications of the REACH registry for vascular surgery].

  Medicina clinica 20090901

• Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion.

  Neuroscience 20090818

• Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells.

  European journal of pharmacology 20090815

• Bare-metal stents versus drug-eluting stents in large (≥3.5mm) single coronary artery: angiographic and clinical outcomes at 6 months.

  Journal of cardiology 20090801

• Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets.

  Thrombosis and haemostasis 20090801

• Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.

  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20090801

• Differences in Clinical Outcomes Between Patients With ST-Elevation Versus Non-ST-Elevation Acute Myocardial Infarction in Korea.

  Korean circulation journal 20090801

• Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.

  The Journal of pharmacology and experimental therapeutics 20090701

• Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time.

  Thrombosis research 20090701

• Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.

  The American journal of cardiology 20090701

• Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies.

  Current vascular pharmacology 20090701

• Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced glycation end products in patients with Wagner grade 0 diabetic foot: a randomized controlled trial.

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20090701

• Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.

  British journal of clinical pharmacology 20090701

• Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  Circulation 20090630

• Drug-eluting stent thrombosis after cilostazol withdrawal in a patient previously treated with triple antiplatelet therapy.

  International journal of cardiology 20090626

• Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.

  Journal of the American College of Cardiology 20090616

• Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages.

  Atherosclerosis 20090601

• Three aneurysms developed in three different drug-eluting stents.

  European heart journal 20090601

• Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.

  AAPS PharmSciTech 20090601

• Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, and prevention.

  Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing 20090601

• Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways.

  The Korean journal of internal medicine 20090601

• Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage.

  Neurologia medico-chirurgica 20090601

• Rapid Hemodynamic Deterioration and Death due to Acute Severe Refractory Septic Shock.

  Journal of clinical medicine research 20090601

• The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation.

  International journal of cardiology 20090529

• Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.

  Neuroreport 20090506

• The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.

  Journal of vascular surgery 20090501

• Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.

  The Journal of pharmacology and experimental therapeutics 20090501

• Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans.

  American journal of physiology. Heart and circulatory physiology 20090501

• Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.

  Circulation journal : official journal of the Japanese Circulation Society 20090501

• Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20090501

• Pharmacologic therapy for intermittent claudication.

  Pharmacotherapy 20090501

• Update on oral antiplatelet therapy: principles, problems and promises.

  Future cardiology 20090501

• Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications.

  Expert reviews in molecular medicine 20090501

• Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation.

  Korean circulation journal 20090501

• Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

  Bioorganic & medicinal chemistry letters 20090415

• Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.

  Life sciences 20090410

• AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.

  Clinical science (London, England : 1979) 20090401

• A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20090401

• Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.

  American heart journal 20090401

• Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.

  Diabetes care 20090401

• Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.

  Prescrire international 20090401

• Cilostazol Attenuates 4-hydroxynonenal-enhanced CD36 Expression on Murine Macrophages via Inhibition of NADPH Oxidase-derived Reactive Oxygen Species Production.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20090401

• Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.

  Journal of the American College of Cardiology 20090331

• Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.

  Neuroscience letters 20090313

• The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20090301

• Successful clopidogrel desensitization after drug-eluting stent implantation.

  The Journal of invasive cardiology 20090301

• Symptomatic intracranial stenosis: best medical treatment vs. intracranial stenting.

  Current opinion in neurology 20090201

• Activation of tyrosine hydroxylase prevents pneumonia in a rat chronic cerebral hypoperfusion model.

  Neuroscience 20090123

• Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.

  Journal of the American College of Cardiology 20090106

• Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.

  Cardiovascular research 20090101

• Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats.

  Experimental neurology 20090101

• Safety and efficacy of percutaneous nephrostolithotomy in patients on anticoagulant therapy.

  The Journal of urology 20090101

• Prevalence of peripheral arterial disease in high-risk patients using ankle-brachial index in general practice: a cross-sectional study.

  International journal of clinical practice 20090101

• The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.

  Vascular and endovascular surgery 20090101

• A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.

  Recent patents on cardiovascular drug discovery 20090101

• [Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs].

  No to hattatsu = Brain and development 20090101

• Cilostazol suppresses neointimal hyperplasia in canine vein grafts.

  Surgery today 20090101

• The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozotocin-induced diabetic rats.

  The Journal of international medical research 20090101

• Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients with intermittent claudication.

  BMC cardiovascular disorders 20090101

• Molecular mechanisms of cell proliferation induced by low power laser irradiation.

  Journal of biomedical science 20090101

• Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.

  BMJ (Clinical research ed.) 20090101

• Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.

  Vascular health and risk management 20090101

• Peripheral arterial disease.

  BMJ clinical evidence 20090101

• Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.

  Cerebrovascular diseases (Basel, Switzerland) 20090101

• Wound care in the geriatric client.

  Clinical interventions in aging 20090101

• Evidence-based management strategies for treatment of chronic wounds.

  Eplasty 20090101

• The Karachi intracranial stenosis study (KISS) Protocol: an urban multicenter case-control investigation reporting the clinical, radiologic and biochemical associations of intracranial stenosis in Pakistan.

  BMC neurology 20090101

• Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.

  Internal medicine (Tokyo, Japan) 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Efficacies of the new paclitaxel-eluting Coroflex Please stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please and Taxus (ECO-PLEASANT) trial: study rationale and design.

  Trials 20090101

• Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20090101

• Mycotic aneurysm of the femoral artery complicating Staphylococcus aureus bacteremia: a case report.

  Cases journal 20090101

• Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

  The International journal of angiology : official publication of the International College of Angiology, Inc 20090101

• Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.

  Life sciences 20081219

• Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats.

  European journal of pharmacology 20081203

• Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription.

  Atherosclerosis 20081201

• The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease.

  Angiology 20081201

• Outcomes of partial nephrectomy in patients on chronic oral anticoagulant therapy.

  The Journal of urology 20081201

• Deep venous thrombosis in stroke patients during rehabilitation phase.

  The Keio journal of medicine 20081201

• Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20081201

• ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

  International journal of chronic obstructive pulmonary disease 20081201

• Tadalafil in the treatment of erectile dysfunction.

  Therapeutics and clinical risk management 20081201

• Safety and efficacy of cilostazol in the management of intermittent claudication.

  Vascular health and risk management 20081201

• Cilostazol reduces PAC-1 expression on platelets in ischemic stroke.

  Journal of clinical neurology (Seoul, Korea) 20081201

• Comparisons between ITT and treatment emergent adverse event analyses.

  Statistics in medicine 20081120

• The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model.

  Spine 20081115

• Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease.

  Gut 20081101

• Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.

  Circulation journal : official journal of the Japanese Circulation Society 20081101

• Regarding 'Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions'.

  Journal of vascular surgery 20081101

• Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging.

  Neurobiology of disease 20081001

• Cilostazol and peripheral arterial disease.

  Expert opinion on pharmacotherapy 20081001

• Prize sessions.

  Indian journal of pharmacology 20081001

• Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.

  Journal of cellular and molecular medicine 20080901

• Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20080901

• A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

  European heart journal 20080901

• NO targets SIRT1: a novel signaling network in endothelial senescence.

  Arteriosclerosis, thrombosis, and vascular biology 20080901

• An oral administration of cilostazol before focal ischemia reduces the infarct volume with delayed cerebral blood flow increase in rats.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20080901

• Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.

  The Korean journal of internal medicine 20080901

• In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol.

  Journal of controlled release : official journal of the Controlled Release Society 20080825

• Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor.

  European journal of pharmacology 20080820

• Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.

  American journal of physiology. Heart and circulatory physiology 20080801

• Peripheral arterial disease: diagnosis and management.

  Mayo Clinic proceedings 20080801

• Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery.

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20080801

• The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy.

  Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology 20080801

• Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20080801

• Vitamin B for treating peripheral neuropathy.

  The Cochrane database of systematic reviews 20080716

• Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.

  Clinical journal of the American Society of Nephrology : CJASN 20080701

• 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts.

  The Journal of pharmacology and experimental therapeutics 20080701

• Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080701

• Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.

  Journal of vascular surgery 20080701

• P-selectin-dependent monocyte recruitment through platelet interaction in intestinal microvessels of LPS-treated mice.

  Microcirculation (New York, N.Y. : 1994) 20080701

• Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol.

  Canadian journal of physiology and pharmacology 20080701

• [Perioperative management of patients with drug-eluting coronary stents presenting for non-cardiac surgery].

  Masui. The Japanese journal of anesthesiology 20080701

• Cilostazol's effect on the response to perivascular nerve stimulation in isolated dog cerebral and mesenteric arteries.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080701

• Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study.

  Stroke 20080601

• Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.

  The Lancet. Neurology 20080601

• Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.

  The Lancet. Neurology 20080601

• Successful radiofrequency catheter ablation for electrical storm of ventricular fibrillation in a patient with Brugada syndrome.

  Circulation journal : official journal of the Japanese Circulation Society 20080601

• Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.

  American heart journal 20080601

• Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.

  Journal of the American Geriatrics Society 20080601

• Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  Chest 20080601

• The impact of initial treatment delay using primary angioplasty on mortality among patients with acute myocardial infarction: from the Korea acute myocardial infarction registry.

  Journal of Korean medical science 20080601

• Very late stent thrombosis after drug-eluting stent implantation in a patient without aspirin and clopidogrel resistance.

  Journal of Korean medical science 20080601

• Antiplatelet drugs in cardiological practice: established strategies and new developments.

  Vascular health and risk management 20080601

• Measurement of platelet-derived microparticle levels in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay.

  The Kobe journal of medical sciences 20080523

• Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats.

  Neuroscience letters 20080509

• Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development.

  Pharmaceutical research 20080501

• Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review.

  Stroke 20080501

• Antithrombotic therapy in peripheral arterial disease.

  Cardiology clinics 20080501

• Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model.

  Circulation journal : official journal of the Japanese Circulation Society 20080501

• [Coronary artery bypass grafting for simultaneous subacute stent thrombosis after sirolimus-eluting stent implantation].

  Kyobu geka. The Japanese journal of thoracic surgery 20080501

• Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats.

  Brain research 20080408

• Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401

• Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.

  American journal of hypertension 20080401

• Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.

  Canadian journal of physiology and pharmacology 20080401

• Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).

  Journal of the American College of Cardiology 20080325

• Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis.

  Arthritis and rheumatism 20080301

• Management of peripheral arterial disease in the elderly: focus on cilostazol.

  Clinical interventions in aging 20080301

• Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).

  Journal of vascular surgery 20080201

• Clopidogrel desensitization: case report and review of published protocols.

  Pharmacotherapy 20080201

• [Pretreatment with cilostazol protects against the vascular endothelial damage after ischemia/reperfusion].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080201

• Cilostazol for peripheral arterial disease.

  The Cochrane database of systematic reviews 20080123

• Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells.

  Journal of cellular biochemistry 20080101

• Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.

  Circulation journal : official journal of the Japanese Circulation Society 20080101

• Novel augmentation therapy with cilostazol for the geriatric major depressive disorder patient with deep white matter hyperintensities on T2-weighted brain MRI: a case report.

  Pharmacopsychiatry 20080101

• Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol.

  Pulmonary pharmacology & therapeutics 20080101

• Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.

  Angiology 20080101

• Platelet activation in bypass surgery for critical limb ischemia.

  Vascular and endovascular surgery 20080101

• Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20080101

• Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

  CNS neuroscience & therapeutics 20080101

• Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.

  Cerebrovascular diseases (Basel, Switzerland) 20080101

• Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs.

  Thrombosis research 20080101

• Pseudoaldosteronism caused by combined administration of cilostazol and glycyrrhizin.

  Internal medicine (Tokyo, Japan) 20080101

• Injuries to the vascular endothelium: vascular wall and endothelial dysfunction.

  Reviews in neurological diseases 20080101

• Effects of cilostazol on thrombospondin-1 (TSP-1) expression changes in the myocardium of diabetic rats.

  The Journal of international medical research 20080101

• Low-dose aspirin prolongs bleeding after gastric biopsy in Japanese patients.

  Thrombosis research 20080101

• Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics.

  Arzneimittel-Forschung 20080101

• Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel.

  Journal of translational medicine 20080101

• Spinal epidural hematoma following epidural catheter removal during antiplatelet therapy with cilostazol.

  Journal of anesthesia 20080101

• Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.

  Cardiovascular toxicology 20080101

• Management of lower extremity peripheral arterial disease.

  Journal of cardiopulmonary rehabilitation and prevention 20080101

• Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke.

  BMC neurology 20080101

• Medical management and cardiovascular risk reduction in peripheral arterial disease.

  Experimental and clinical cardiology 20080101

• Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes.

  Drug design, development and therapy 20080101

• Hydrolytic Degradation Profile and RP-HPLC Estimation of Cilostazol in Tablet Dosage Form.

  Indian journal of pharmaceutical sciences 20080101

• Hemorrhagic cholecystitis in an elderly patient taking aspirin and cilostazol.

  Case reports in gastroenterology 20080101

• Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats.

  Brain research 20071214

• Seven cases of late-life depression treated with cilostazol-augmented therapy.

  Journal of clinical psychopharmacology 20071201

• Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.

  Circulation journal : official journal of the Japanese Circulation Society 20071201

• [Three cases of internal carotid artery dissection due to trivial trauma].

  No shinkei geka. Neurological surgery 20071201

• Pharmacologic prevention of aspiration pneumonia: a systematic review.

  The American journal of geriatric pharmacotherapy 20071201

• [Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol].

  Arquivos brasileiros de endocrinologia e metabologia 20071201

• Peripheral arterial disease in the elderly.

  Clinical interventions in aging 20071201

• Induced hypertensive therapy in an acute ischemic stroke patient with early neurological deterioration.

  Journal of clinical neurology (Seoul, Korea) 20071201

• Long-term outcome of simultaneous kissing stenting technique with sirolimus-eluting stent for large bifurcation coronary lesions.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20071115

• [Marked effectiveness of cilostazol in a case of hemodynamic TIA].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20071110

• Validated stability-indicating methods for determination of cilostazol in the presence of its degradation products according to the ICH guidelines.

  Journal of pharmaceutical and biomedical analysis 20071105

• Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.

  Circulation journal : official journal of the Japanese Circulation Society 20071101

• Cilostazol: a new drug in the treatment intermittent claudication.

  Recent patents on cardiovascular drug discovery 20071101

• The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.

  Cardiovascular drugs and therapy 20071001

• Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• The power of drug co-administration: smaller doses better outcomes.

  Cardiovascular drugs and therapy 20071001

• Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice.

  Journal of clinical pharmacy and therapeutics 20071001

• Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).

  The American journal of cardiology 20071001

• Cilostazol inhibits monocytic cell adhesion to vascular endothelium via upregulation of cAMP.

  Journal of atherosclerosis and thrombosis 20071001

• Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model.

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20071001

• [Inhibition of L-arginine and cilostazol on activation of platelets in vitro].

  Zhongguo shi yan xue ye xue za zhi 20071001

• Pharmacologic approaches to restenosis prevention.

  The American journal of cardiology 20070903

• Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.

  Blood 20070901

• Medical therapy for intermittent claudication.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20070901

• NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.

  Life sciences 20070901

• Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary artery disease and diabetic nephropathy: a single center experience.

  The Korean journal of internal medicine 20070901

• [Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention].

  Zhonghua xin xue guan bing za zhi 20070901

• Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.

  The American journal of cardiology 20070815

• Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.

  Pharmacological research 20070801

• Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats.

  Brain research 20070709

• Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.

  Journal of medicinal chemistry 20070614

• Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat.

  Brain research 20070604

• Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.

  American journal of physiology. Heart and circulatory physiology 20070601

• Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation.

  Heart rhythm 20070601

• Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.

  International journal of clinical pharmacology and therapeutics 20070601

• Risk reduction with clopidogrel in the management of peripheral arterial disease.

  Vascular health and risk management 20070601

• Nanoparticulate carriers for the treatment of coronary restenosis.

  International journal of nanomedicine 20070601

• Clinical aspects of platelet inhibitors and thrombus formation.

  Circulation research 20070511

• Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats.

  Digestive diseases and sciences 20070501

• Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor.

  Life sciences 20070410

• Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol.

  Circulation journal : official journal of the Japanese Circulation Society 20070401

• Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions.

  Journal of thrombosis and haemostasis : JTH 20070401

• Induction of metallothionein synthesis by cilostazol in mice and in human cultured neuronal cell lines.

  Biological & pharmaceutical bulletin 20070401

• Epidemiology, classification, and modifiable risk factors of peripheral arterial disease.

  Vascular health and risk management 20070401

• Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?

  Circulation 20070327

• Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects.

  British journal of clinical pharmacology 20070301

• Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines.

  Nature clinical practice. Cardiovascular medicine 20070301

• Examination of anti-intima hyperplastic effect on cilostazol-eluting stent in a porcine model.

  The Journal of invasive cardiology 20070301

• Cilostazol in the management of vascular disease.

  International angiology : a journal of the International Union of Angiology 20070301

• Investigation of binding proteins for anti-platelet agent K-134 by Drug-Western method.

  Biochemical and biophysical research communications 20070223

• Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.

  European journal of pharmacology 20070214

• Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation.

  Pharmacological research 20070201

• Ionic basis of pharmacological therapy in Brugada syndrome.

  Journal of cardiovascular electrophysiology 20070201

• Optimal management of platelet function after coronary stenting.

  Current treatment options in cardiovascular medicine 20070201

• A validated stability indicating high performance reverse phase liquid chromatographic method for the determination of cilostazol in bulk drug substance.

  Drug development and industrial pharmacy 20070201

• Cilostazol for peripheral arterial disease.

  The Cochrane database of systematic reviews 20070124

• Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.

  Thrombosis research 20070101

• Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function.

  Circulation journal : official journal of the Japanese Circulation Society 20070101

• The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial.

  Journal of vascular surgery 20070101

• In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.

  Nuclear medicine and biology 20070101

• Peripheral arterial disease.

  Geriatrics 20070101

• Peripheral arterial disease: diagnosis, treatment, and systemic implications.

  Clinics in dermatology 20070101

• Current management of peripheral arterial occlusive disease: a review of pharmacologic agents and other interventions.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

• improved patency of transjugular intrahepatic portosystemic shunt: the efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models.

  Cardiovascular and interventional radiology 20070101

• Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice.

  Arzneimittel-Forschung 20070101

• Approach to the asymptomatic patients with Brugada syndrome.

  Indian pacing and electrophysiology journal 20070101

• All patients benefit equally from a supervised exercise program for claudication.

  Vascular and endovascular surgery 20070101

• Association between erythrocyte Na+K+-ATPase activity and some blood lipids in type 1 diabetic patients from Lagos, Nigeria.

  BMC endocrine disorders 20070101

• The endothelium, platelets, and brain ischemia.

  Reviews in neurological diseases 20070101

• Management of peripheral arterial disease of the lower extremities.

  Comprehensive therapy 20070101

• Cilostazol, a cAMP phosphodiesterase 3 inhibitor, in the treatment of poststroke depression.

  The Journal of neuropsychiatry and clinical neurosciences 20070101

• [Organic cause of emotional depression].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20070101

• The management of Brugada syndrome patients.

  Cardiology journal 20070101

• Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.

  Atherosclerosis 20061201

• Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.

  Thrombosis and haemostasis 20061201

• High-frequency potentials developed in wavelet-transformed electrocardiogram as a novel indicator for detecting Brugada syndrome.

  Heart rhythm 20061201

• Peripheral arterial disease: a review of disease awareness and management.

  The American journal of geriatric pharmacotherapy 20061201

• Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice.

  Shock (Augusta, Ga.) 20061101

• The headache-inducing effect of cilostazol in human volunteers.

  Cephalalgia : an international journal of headache 20061101

• Established and evolving medical therapies for claudication in patients with peripheral arterial disease.

  Nature clinical practice. Cardiovascular medicine 20061101

• Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis.

  Arquivos brasileiros de cardiologia 20061101

• [Basic principal of the dual antithrombotic therapy achieved by cilostazol].

  Nihon rinsho. Japanese journal of clinical medicine 20061028

• Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2.

  Brain research 20061020

• Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation.

  Pharmacological research 20061001

• Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.

  American heart journal 20061001

• Contemporary management of peripheral arterial disease: II. Improving walking distance and quality of life.

  Cleveland Clinic journal of medicine 20061001

• Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors.

  International journal of clinical practice 20060801

• [The effects of post coronary stenting triple antiplatelet therapies on platelet functions].

  Zhonghua nei ke za zhi 20060801

• Oral antiplatelet agents and bleeding risk in relation to major cardiovascular surgery.

  Current drug safety 20060801

• Cilostazol suppresses adhesion of human neutrophils to HUVECs stimulated by FMLP and its mechanisms.

  Life sciences 20060710

• Medical management of peripheral arterial disease.

  JAMA 20060705

• Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression.

  The Journal of pharmacology and experimental therapeutics 20060701

• Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.

  The Journal of invasive cardiology 20060701

• Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation.

  The Journal of pharmacology and experimental therapeutics 20060601

• Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion.

  Stroke 20060601

• Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents.

  The Annals of pharmacotherapy 20060601

• Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.

  Methods and findings in experimental and clinical pharmacology 20060601

• Peripheral arterial disease.

  Clinical evidence 20060601

• Exercise and peripheral arterial disease.

  Annals of internal medicine 20060502

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• [Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention].

  Zhonghua yi xue za zhi 20060425

• Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.

  Brain research 20060412

• Diosgenin, a plant-derived sapogenin, stimulates Ca2+-activated K+ current in human cortical HCN-1A neuronal cells.

  Planta medica 20060401

• Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction.

  Circulation journal : official journal of the Japanese Circulation Society 20060401

• Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.

  Journal of controlled release : official journal of the Controlled Release Society 20060310

• A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.

  Chinese medical journal 20060305

• Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.

  Clinical pharmacology and therapeutics 20060301

• [A case of carotid stenting via the transbrachial approach in the bovine arch].

  No shinkei geka. Neurological surgery 20060301

• Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.

  International heart journal 20060301

• [A case of vertebral artery dissection with recurrent brain embolism].

  No to shinkei = Brain and nerve 20060301

• Changes in membrane cholesterol of pituitary tumor (GH3) cells regulate the activity of large-conductance Ca2+-activated K+ channels.

  The Chinese journal of physiology 20060227

• Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry.

  Analytical and bioanalytical chemistry 20060201

• Medical treatment of peripheral arterial disease.

  JAMA 20060201

• The vascular effects of cilostazol.

  The Canadian journal of cardiology 20060201

• Medical management of peripheral arterial disease: a therapeutic algorithm.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20060201

• Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome.

  Journal of cardiovascular electrophysiology 20060201

• Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.

  Journal of vascular research 20060101

• Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia.

  Stroke 20060101

• Cilostazol: therapeutic potential against focal cerebral ischemic damage.

  Current pharmaceutical design 20060101

• Antiplatelet therapy in stroke prevention: present and future.

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• New modalities and aspects of antiplatelet therapy for stroke prevention.

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy?

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• Antiplatelet therapy after percutaneous coronary intervention.

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• Drug treatment of peripheral arterial disease in the elderly.

  Drugs & aging 20060101

• Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats.

  Journal of gastroenterology 20060101

• Therapy for the Brugada syndrome.

  Handbook of experimental pharmacology 20060101

• Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.

  Cerebrovascular diseases (Basel, Switzerland) 20060101

• Pharmacological roles of the large-conductance calcium-activated potassium channel.

  Current topics in medicinal chemistry 20060101

• Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• Haemostasis, inflammation and renal function following exercise in patients with intermittent claudication on statin and aspirin therapy.

  Thrombosis journal 20060101

• Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study).

  Cardiovascular diabetology 20060101

• Optimal medical management of peripheral arterial disease.

  Vascular and endovascular surgery 20060101

• Elevation of intracellular cAMP up-regulated thrombomodulin mRNA in cultured vascular endothelial cells derived from spontaneous type-II diabetes mellitus model rat.

  Endothelium : journal of endothelial cell research 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• Cerebrovascular effects of cilostazol in patients with atherosclerotic disease.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20060101

• Platelet aggregation inhibitors in primary and secondary prevention of ischemic stroke.

  GMS health technology assessment 20060101

• Role of adjunct pharmacologic therapy in the era of drug-eluting stents.

  Atherosclerosis. Supplements 20051215

• Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study.

  Atherosclerosis. Supplements 20051215

• The US experience with cilostazol in treating intermittent claudication.

  Atherosclerosis. Supplements 20051215

• A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.

  Atherosclerosis. Supplements 20051215

• Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.

  Atherosclerosis. Supplements 20051215

• Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.

  Atherosclerosis. Supplements 20051215

• The vulnerable carotid artery plaque: current imaging methods and new perspectives.

  Stroke 20051201

• [Treatment of peripheral obstructive artery disease: a battle that could be winned also with drugs?].

  Minerva cardioangiologica 20051201

• Muscle infarction involving muscles of abdominal and thoracic walls in diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20051201

• Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.

  The Journal of biological chemistry 20051125

• Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.

  Journal of the American College of Cardiology 20051115

• Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats.

  American journal of physiology. Heart and circulatory physiology 20051101

• Coronary stent restenosis in patients treated with cilostazol.

  Circulation 20051101

• Prevention of restenosis by systemic drug therapy: back to the future?

  Circulation 20051101

• [Effects of cilostazol on long-term clinical outcomes after coronary stenting].

  Zhonghua nei ke za zhi 20051101

• P >0.05 not equal equivalent or noninferior.

  The American journal of cardiology 20051001

• Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.

  Circulation journal : official journal of the Japanese Circulation Society 20051001

• Drug therapy in Brugada syndrome.

  Current drug targets. Cardiovascular & haematological disorders 20051001

• Preventive strategies for aspiration pneumonia in elderly disabled persons.

  The Tohoku journal of experimental medicine 20050901

• Evidence-based management of peripheral vascular disease.

  Current atherosclerosis reports 20050901

• Cilostazol improves long-term outcomes after coronary stent implantation.

  American heart journal 20050901

• Commentary. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.

  Perspectives in vascular surgery and endovascular therapy 20050901

• RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.

  Journal of cardiovascular pharmacology 20050801

• Hypereosinophilia presenting as eosinophilic vasculitis and multiple peripheral artery occlusions without organ involvement.

  Journal of Korean medical science 20050801

• Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.

  Neurological research 20050701

• Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.

  Circulation journal : official journal of the Japanese Circulation Society 20050701

• Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.

  Current medical research and opinion 20050601

• Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.

  The Journal of pharmacology and experimental therapeutics 20050501

• Effects of cilostazol on human venous smooth muscle.

  Annals of vascular surgery 20050501

• Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F.

  Hypertension (Dallas, Tex. : 1979) 20050401

• Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.

  Stroke 20050401

• Comparison of cilostazol and clopidogrel after successful coronary stenting.

  The American journal of cardiology 20050401

• Percutaneous coronary intervention versus coronary artery bypass grafting for diabetics with multivessel coronary artery disease: the Korean Multicenter Revascularization Registry (KORR).

  Journal of Korean medical science 20050401

• [Significance of the stool occult blood test in patients with thrombotic disease under treatment with low dose aspirin].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050401

• Intracranial atherosclerosis: incidence, diagnosis and treatment.

  Journal of clinical neurology (Seoul, Korea) 20050401

• Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation.

  The Journal of pharmacology and experimental therapeutics 20050301

• Inhibition of eosinophil survival by a selective inhibitor of phosphodiesterase 4 via the induction of apoptosis.

  Biological & pharmaceutical bulletin 20050301

• Effects of cilostazol on lipid and fatty acid metabolism.

  Clinical and experimental medicine 20050301

• Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents.

  Thrombosis research 20050101

• Management of peripheral arterial disease.

  Cardiology in review 20050101

• Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic.

  Cardiology in review 20050101

• Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.

  International heart journal 20050101

• Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.

  Cardiovascular drugs and therapy 20050101

• Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.

  Current pharmaceutical design 20050101

• Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.

  Journal of managed care pharmacy : JMCP 20050101

• Phosphodiesterase 3 inhibition and cough in elderly asthmatics.

  Cough (London, England) 20050101

• Prevalence of antiplatelet therapy in patients with diabetes.

  Cardiovascular diabetology 20050101

• Inhibition of platelet activation and aggregation.

  Handbook of experimental pharmacology 20050101

• Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options.

  Indian pacing and electrophysiology journal 20050101

• The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20041201

• Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.

  American heart journal 20041201

• Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.

  Endocrine journal 20041201

• Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.

  The Korean journal of internal medicine 20041201

• The top 12 advances in vascular medicine.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20041201

• Peripheral arterial disease.

  Clinical evidence 20041201

• Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat.

  Metabolism: clinical and experimental 20041101

• Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.

  Journal of the American College of Cardiology 20041006

• The role of cilostazol in the treatment of intermittent claudication.

  Current medical research and opinion 20041001

• Not just another restenosis trial.

  Clinical cardiology 20041001

• Sinus node dysfunction associated with discontinuation of cilostazol in a patient taking atenolol.

  British journal of anaesthesia 20040901

• Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production.

  Microvascular research 20040901

• Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20040901

• Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts.

  The Journal of thoracic and cardiovascular surgery 20040901

• Treatment of disability in peripheral arterial disease: new drugs.

  Current drug targets. Cardiovascular & haematological disorders 20040901

• Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  Chest 20040901

• Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.

  Circulation 20040831

• Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.

  Journal of cardiovascular pharmacology 20040801

• The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents.

  Pancreas 20040801

• A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20040801

• Treatment of intermittent claudication: cilostazol.

  Hospital medicine (London, England : 1998) 20040801

• Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis.

  Seminars in thrombosis and hemostasis 20040801

• Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.

  Platelets 20040801

• [Effect of cilostazol on transient outward potassium current in human atrial myocytes].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20040801

• Cilostazol: improving walking distance in patients with intermittent claudication.

  Expert review of cardiovascular therapy 20040701

• Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.

  Circulation journal : official journal of the Japanese Circulation Society 20040701

• Deterioration of vascular dementia caused by recurrent multiple small emboli from thoracic aortic atheroma.

  Internal medicine (Tokyo, Japan) 20040701

• Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20040601

• Inhibitory actions of cilostazol on electrical responses of smooth muscle isolated from the guinea-pig stomach antrum.

  Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20040601

• Peripheral arterial disease.

  Clinical evidence 20040601

• [Secondary prevention and conservative therapy of obliterative arteriosclerosis].

  Orvosi hetilap 20040516

• Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.

  The Journal of invasive cardiology 20040501

• Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.

  Platelets 20040501

• Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.

  Cardiovascular drugs and therapy 20040501

• An unusual cause of exertional leg pain.

  Current sports medicine reports 20040401

• How reliable is preliminary evidence?

  Journal of wound care 20040401

• Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels.

  Blood 20040315

• Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol.

  Circulation 20040302

• Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats.

  The Journal of pharmacology and experimental therapeutics 20040301

• Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.

  Endocrinology 20040301

• Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease.

  British journal of clinical pharmacology 20040301

• Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20040301

• Conservative regimen for chronic critical limb ischemia.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20040301

• Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.

  Circulation 20040224

• Drugs for intermittent claudication.

  The Medical letter on drugs and therapeutics 20040216

• Management of peripheral arterial disease.

  American family physician 20040201

• Management of peripheral arterial disease of the lower extremities in elderly patients.

  The journals of gerontology. Series A, Biological sciences and medical sciences 20040201

• Foot ulceration due to arterial insufficiency: role of cilostazol.

  Journal of wound care 20040201

• Cilostazol enhances casein kinase 2 phosphorylation and suppresses tumor necrosis factor-alpha-induced increased phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and apoptotic cell death in SK-N-SH cells.

  The Journal of pharmacology and experimental therapeutics 20040101

• A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion.

  Journal of pharmacological and toxicological methods 20040101

• Effects of antiplatelet agents on pulmonary haemodynamic response to fMLP in endotoxin primed rats.

  Thorax 20040101

• Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy.

  Journal of the American Pharmacists Association : JAPhA 20040101

• The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma.

  Respiratory research 20040101

• Drug treatment of intermittent claudication.

  Drugs 20040101

• Chronotropic effect of the antithrombotic agent cilostazol in a patient with sick sinus syndrome and syncope.

  The Journal of international medical research 20040101

• Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.

  Drugs 20040101

• Role of pharmacotherapy in Brugada syndrome.

  Indian pacing and electrophysiology journal 20040101

• Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats--an MRI study.

  Brain research 20031219

• Effects of cilostazol in patients with Raynaud's syndrome.

  The American journal of cardiology 20031201

• Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.

  Atherosclerosis 20031201

• Medical treatment of peripheral arterial disease.

  Current opinion in cardiology 20031101

• Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug.

  Journal of pharmaceutical sciences 20031101

• [EBM of cerebral infarction: message from mega-studies].

  Rinsho shinkeigaku = Clinical neurology 20031101

• Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.

  Journal of vascular surgery 20031001

• Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.

  Clinical cardiology 20031001

• Age-dependent changes in the regulatory roles of nitric oxide and vasodilator prostanoids on the mechanical activities of isolated rabbit spinal arterioles.

  The Japanese journal of physiology 20031001

• Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.

  American journal of respiratory cell and molecular biology 20030901

• Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation.

  The Journal of pharmacology and experimental therapeutics 20030901

• Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature.

  Japanese heart journal 20030901

• Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets.

  Platelets 20030901

• Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.

  Journal of the Indian Medical Association 20030901

• [Peripheral arterial occlusive disease (PAVK)].

  VASA. Zeitschrift fur Gefasskrankheiten 20030801

• Interventions to prevent aspiration pneumonia in older adults: a systematic review.

  Journal of the American Geriatrics Society 20030701

• Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris.

  The American journal of cardiology 20030701

• Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.

  Prostaglandins & other lipid mediators 20030701

• The role of cilostazol (Pletal) in the management of intermittent claudication.

  International journal of clinical practice 20030601

• The case for early detection and integrated intervention in patients with peripheral arterial disease and intermittent claudication.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20030601

• Peripheral arterial disease.

  Clinical evidence 20030601

• A paclitaxel-eluting stent for the prevention of coronary restenosis.

  The New England journal of medicine 20030417

• Cilostazol: an 'intermittent claudication' remedy for the management of third-degree AV block.

  Chest 20030401

• Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block.

  Chest 20030401

• Pharmacotherapy as adjunctive treatment for serious foot wounds in the patient with diabetes: a case study.

  Ostomy/wound management 20030401

• Management of thrombotic and cardiovascular disorders in the new millenium.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20030401

• Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.

  Clinical and experimental medicine 20030201

• Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells.

  Journal of cardiovascular pharmacology 20030101

• Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers.

  Journal of atherosclerosis and thrombosis 20030101

• Cilostazol as a unique antithrombotic agent.

  Current pharmaceutical design 20030101

• [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs].

  Yakushigaku zasshi 20030101

• Cilostazol: a review of its use in intermittent claudication.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20030101

• Recovery of platelet function after withdrawal of cilostazol administered orally for a long period.

  Journal of atherosclerosis and thrombosis 20030101

• Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.

  The American journal of cardiology 20021215

• Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells.

  American journal of physiology. Cell physiology 20021201

• Thermally-prepared polymorphic forms of cilostazol.

  Journal of pharmaceutical sciences 20021201

• Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.

  Journal of clinical pharmacology 20021201

• Spontaneous recanalization of arterial occlusions: an unusual mechanism for symptomatic improvement.

  Journal of vascular surgery 20021201

• Pharmacologic therapy for peripheral arterial disease and claudication.

  Journal of vascular surgery 20021201

• Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.

  Journal of the American Geriatrics Society 20021201

• Can claudication be improved with medication?

  Seminars in vascular surgery 20021201

• Peripheral arterial disease.

  Clinical evidence 20021201

• Management of patients with intermittent claudication.

  International journal of clinical practice 20021101

• New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.

  Journal of cardiovascular pharmacology 20021001

• Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20021001

• Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.

  The Japanese journal of physiology 20021001

• Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).

  The American journal of cardiology 20020915

• Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.

  Molecular pharmacology 20020901

• [State of treatment of coronary artery disease by drug releasing stents].

  Herz 20020901

• Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.

  Cardiovascular drugs and therapy 20020901

• Polymorphic forms of cilostazol.

  Acta crystallographica. Section C, Crystal structure communications 20020801

• Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.

  American heart journal 20020801

• Cilostazol enhances IL-1beta-induced NO production and apoptosis in rat vascular smooth muscle via PKA-dependent pathway.

  Cellular signalling 20020701

• Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20020701

• Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.

  Journal of cardiovascular electrophysiology 20020701

• [Effect of cilostazol on adhesion molecules of STZ-induced diabetic rats].

  Zhonghua yi xue za zhi 20020610

• [Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].

  Zeitschrift fur Kardiologie 20020601

• Peripheral arterial disease.

  Clinical evidence 20020601

• A rational approach to diagnosis and treatment of intermittent claudication.

  The American journal of the medical sciences 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.

  Clinical pharmacology and therapeutics 20020401

• The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats.

  Life sciences 20020315

• Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.

  The Journal of pharmacology and experimental therapeutics 20020301

• Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.

  Clinical cardiology 20020301

• Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans.

  Circulation journal : official journal of the Japanese Circulation Society 20020301

• Recent advances in antiplatelet agents.

  Current medicinal chemistry 20020301

• The pharmacology of cilostazol.

  Diabetes, obesity & metabolism 20020301

• Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.

  Diabetes, obesity & metabolism 20020301

• Treating peripheral arterial disease in patients with diabetes.

  Diabetes, obesity & metabolism 20020301

• Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.

  The Journal of pharmacology and experimental therapeutics 20020201

• Cilostazol.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020201

• A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.

  Diabetologia 20020201

• The ten most commonly asked questions about management of peripheral arterial disease.

  Cardiology in review 20020101

• Current medical therapies for patients with peripheral arterial disease: a critical review.

  The American journal of medicine 20020101

• Cilostazol in intermittent claudication.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020101

• Successful pharmacologic treatment of lower extremity ulcerations in 5 patients with chronic critical limb ischemia.

  The Journal of the American Board of Family Practice 20020101

• [Etiology, pathogenesis and management of senile inflammatory pulmonary diseases].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20020101

• Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.

  Vascular and endovascular surgery 20020101

• Rapid ventricular tachycardias associated with cilostazol use.

  Texas Heart Institute journal 20020101

• Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.

  Angiology 20020101

• Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.

  Angiology 20020101

• Cilostazol treatment of claudication in diabetic patients.

  Current medical research and opinion 20020101

• Pharmacologic treatment for intermittent claudication.

  Vascular medicine (London, England) 20020101

• Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.

  Clinical and experimental immunology 20011201

• Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20011101

• Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.

  Journal of cardiovascular pharmacology 20011101

• What can I do to continue walking despite intermittent claudication?

  The Johns Hopkins medical letter health after 50 20011101

• Pharmacotherapy of intermittent claudication.

  Expert opinion on pharmacotherapy 20011101

• Three cases of digital ischemia successfully treated with cilostazol.

  Vascular medicine (London, England) 20011101

• Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.

  The American journal of cardiology 20011011

• Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.

  Atherosclerosis 20011001

• Antiplatelet agent cilostazol potentiates adipocyte differentiation of 3T3-L1 cells.

  Atherosclerosis 20010901

• Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence.

  Atherosclerosis 20010901

• Hepatothermic therapy of obesity: rationale and an inventory of resources.

  Medical hypotheses 20010901

• Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.

  Clinical science (London, England : 1979) 20010901

• Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.

  The Annals of pharmacotherapy 20010901

• Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta.

  Life sciences 20010831

• Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.

  Diabetologia 20010801

• Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.

  British journal of pharmacology 20010801

• Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies.

  The American journal of cardiology 20010628

• Intermittent claudication: effective medical management of a common circulatory problem.

  The American journal of cardiology 20010628

• Comparative effects of cilostazol and other therapies for intermittent claudication.

  The American journal of cardiology 20010628

• Analysis of the cilostazol safety database.

  The American journal of cardiology 20010628

• The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.

  The Korean journal of internal medicine 20010601

• Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.

  International journal of cardiology 20010501

• Antithrombotic therapy for prevention of pneumonia.

  Journal of the American Geriatrics Society 20010501

• Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20010401

• [Pressure wire guide provisional coronary stent implantation].

  Journal of cardiology 20010401

• A new treatment for peripheral arterial disease.

  Harvard heart letter : from Harvard Medical School 20010401

• Cilostazol: a novel treatment option in intermittent claudication.

  International journal of clinical practice. Supplement 20010401

• New treatment options in intermittent claudication: the US experience.

  International journal of clinical practice. Supplement 20010401

• Treatment of intermittent claudication with pentoxifylline and cilostazol.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010315

• Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.

  Thrombosis research 20010315

• Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?

  The Journal of family practice 20010201

• Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes.

  European journal of pharmacology 20010112

• Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.

  American heart journal 20010101

• Novel platelet inhibitors.

  Annual review of medicine 20010101

• Cilostazol: treatment of intermittent claudication.

  The Annals of pharmacotherapy 20010101

• Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20010101

• [Effects of cilostazol in patients with bradycardiac atrial fibrillation].

  Journal of cardiology 20010101

• Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  Japanese heart journal 20010101

• Medical management of peripheral arterial disease.

  Cardiology in review 20010101

• Management of peripheral arterial disease and intermittent claudication.

  The Journal of the American Board of Family Practice 20010101

• Effect of cilostazol on endothelial cell denudation and proliferation in canine vein grafts.

  Surgery today 20010101

• Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication.

  Vascular medicine (London, England) 20010101

• Peripheral arterial disease.

  Advances in internal medicine 20010101

• Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

  Cardiovascular drug reviews 20010101

• Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20010101

• Cilostazol prevents impairment of slow axonal transport in streptozotocin-diabetic rats.

  European journal of pharmacology 20001201

• Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.

  Biochemical pharmacology 20000215

• Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21.

  Hypertension (Dallas, Tex. : 1979) 20000101

• Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.

  Pharmacological research 19950201

• Increased external carotid artery blood flow in headache patients induced by cilostazol. Preliminary communication.

  Arzneimittel-Forschung 19900501